- Report
- August 2025
- 186 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- January 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Drug Pipelines
- April 2025
- 50 Pages
Global
From €1310EUR$1,500USD£1,138GBP
- Report
- February 2022
- 220 Pages
Global
From €8296EUR$9,500USD£7,207GBP
- Report
- March 2024
- 159 Pages
Global
From €6943EUR$7,950USD£6,031GBP
- Report
- September 2025
- 50 Pages
Global
From €2314EUR$2,650USD£2,010GBP
- Report
- September 2025
- 50 Pages
Global
From €2314EUR$2,650USD£2,010GBP
Hydralazine is a medication used to treat high blood pressure and congestive heart failure. It is a vasodilator, meaning it relaxes the muscles in the walls of the blood vessels, allowing them to widen and reducing the pressure of the blood flowing through them. It is often used in combination with other medications to treat hypertension and heart failure. Hydralazine is also used to treat angina, or chest pain caused by reduced blood flow to the heart.
Hydralazine is a generic drug, meaning it is available in many different forms and from many different manufacturers. It is available in both oral and injectable forms, and is often prescribed in combination with other medications.
Hydralazine is a widely used medication in the cardiovascular drug market. It is used to treat a variety of conditions, and is often prescribed in combination with other medications. It is a generic drug, meaning it is available from many different manufacturers.
Some companies in the Hydralazine market include Mylan, Teva Pharmaceuticals, Sandoz, and Pfizer. Show Less Read more